Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

4(66.7%)

Phase 3

1(16.7%)

N/A

1(16.7%)

6Total

Phase 4(4)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT00610402Completed

Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Role: collaborator

NCT04400799Phase 3Terminated

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Role: collaborator

NCT04993534Not ApplicableUnknown

RESPOND: Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns Resulting From the COVID-19 Pandemic

Role: collaborator

NCT04653428Recruiting

German Registry for Transcatheter Tricuspid Valve Interventions

Role: collaborator

NCT04053998Completed

Benchmarking Outcomes in Pancreatic Surgery - WhippleBenchmarks.Org

Role: collaborator

NCT01357707Completed

Clinical-genetic Investigations in Children With Early Infantile Epilepsies

Role: collaborator

NCT02187263Unknown

German Centre for Cardiovascular Research Cardiomyopathy Register

Role: collaborator

NCT00159081Phase 4Completed

One Year Drug Treatment in First-Episode Schizophrenia

Role: collaborator

NCT00159133Phase 4Completed

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Role: collaborator

NCT00159120Phase 4Completed

Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia

Role: collaborator

NCT00157378Phase 4Unknown

Optimization of Acute Treatment in First Episode Schizophrenia

Role: collaborator

All 11 trials loaded